VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) is scheduled to present updates on two of its programs at the World Vaccine Congress on Tuesday, April 11, 2017 at 3:40 PM ET and 4:40 PM ET. The event is being held at the Grand Hyatt in Washington, D.C.

VBI-1901: Harnessing Foreign Viral CMV Antigens to Re-Stimulate Anti-Tumor Immunity

Tuesday, April 11 - 3:40 PM ET

During the Cancer & Immunotherapy Sub-Conference, David E. Anderson, Ph.D., VBI’s Chief Scientific Officer, will provide an overview of VBI’s use of its eVLP Platform directed against cytomegalovirus (“CMV”) to target solid tumors that express CMV antigens. Dr. Anderson will present new preclinical biodistribution and immunogenicity data that supports Phase I/IIa development plans for VBI’s therapeutic vaccine candidate to treat glioblastoma multiforme (“GBM”), one of the most common and aggressive forms of brain cancer. Download Presentation

Sci-B-Vac®: Hepatitis B Vaccine Phase III Program Update

Tuesday, April 11 - 4:40 PM ET

Francisco Diaz-Mitoma, M.D., Ph.D., VBI’s Chief Medical Officer, will present clinical data on Sci-B-Vac, VBI’s third-generation hepatitis B vaccine. This data supports VBI’s proposed global Phase III clinical program, for which the company is seeking evaluation and approval from the U.S. Food and Drug Administration (“FDA”), Health Canada and the European Medical Agency (“EMA”). Download Presentation

Now in its 17th year, the World Vaccine Congress is a well-established global vaccine event attended by international industry leaders, including leading research institutions, government regulators, and life sciences companies.

Dr. Anderson’s and Dr. Diaz-Mitoma’s presentations will be available on VBI’s website, www.vbivaccines.com, following the event.

Event Details